A phase I/II clinical trial at the NIH Clinical Center evaluates the effectiveness of a combination of two agents that may work in complementary ways to target inoperable or metastatic neuroendocrine tumoors. One agent, lutathera, emits radiation inside the body, causing DNA damage, and the second agent, olaparib, a PARP inhibitor, blocks the repair of DNA breaks. The trial commences in Oct 2022 running for approximately 2 years 9 months.
It’s a type of Peptide Receptor Radionuclide Therapy (PRRT) and has been in use for some years as a standard of care (mostly second line). Read more click here.
Olaparib (AZD-2281, trade name Lynparza) is an FDA-approved targeted therapy for cancer, developed by KuDOS Pharmaceuticals and later by AstraZeneca. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair.
Once injected, Lutathera circulates throughout the body and targets the radiation specifically to these neuroendocrine tumour cells, including tumours that might not even be visible on CT scans and other imaging. This focused radiation kills tumour cells by damaging their DNA, and Olaparib is expected to further its effectiveness by preventing the tumour cells from repairing their DNA, i.e. inhibition of PARP results in an antineoplastic effect.
This phase 1, single arm, single centre study at PeterMac Melbourne is designed to evaluate the safety and tolerability of talazoparib in combination with 177Lu-DOTA-Octreotate in patients with metastatic NET (PARLuNET (protocol number 20/163)). It is hoped that of a combination of two agents that may work in complementary ways to target inoperable or metastatic neuroendocrine tumours. One agent, lutathera, emits radiation inside the body, causing DNA damage, and the second agent, talazoparib, a PARP inhibitor, blocks the repair of DNA breaks. The trial commences December 2021 and runs for approximately 4 years.
It’s a type of Peptide Receptor Radionuclide Therapy (PRRT) and has been in use for some years as a standard of care (mostly second line). Read more click here.
Talazoparib is a poly-ADP ribose polymerase inhibitor used to treat HER2-, BRCA mutated locally advanced or metastatic breast cancer. (BNM-673, trade name Talzenna) is approved by FDA/UK NHS and many other countries as a targeted therapy for certain cancers, developed by Pfizer. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair.
Once injected, Lutathera circulates throughout the body and targets the radiation specifically to these neuroendocrine tumour cells, including tumours that might not even be visible on CT scans and other imaging. This focused radiation kills tumour cells by damaging their DNA, and PARP inhibitor is expected to further its effectiveness by preventing the tumour cells from repairing their DNA, i.e. inhibition of PARP results in an antineoplastic effect.
The first thing that struck me was the term inoperable in one of the trial names. This gives an additional option for those with inoperable tumours (including metastases). While it is already an option for inoperable patients, the added punch of a PARP inhibitor gives them a better chance of reducing tumour cells.
Secondly, if PARP is seen to improve the efficiency of PRRT generally, that is of benefit to all those prescribed this therapy, regardless of inoperable status.
1. NIH ClinicalTrials.gov Identifier: NCT04086485
2. NCI Summary for the NIH trial: Read here (with apologies for old nomenclature, disappointing really in my opinion)
3. Australian ClinicalTrials.gov Identifier: NCT05053854
4. Article discussion the Australian trial: Read here.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided in the clinical trials document. It’s very important to check the trial inclusion and exclusion criteria before making any contact. If you need questions, the articles here is very useful Questions to Ask About Clinical Trials | Cancer.Net
The inclusion of any trial within this blog should not be taken as a recommendation by Ronny Allan.
I am not a doctor or any form of medical professional, practitioner or counsellor. None of the information on my website, or linked to my website(s), or conveyed by me on any social media or presentation, should be interpreted as medical advice given or advised by me.
Neither should any post or comment made by a follower or member of my private group be assumed to be medical advice, even if that person is a healthcare professional. Some content may be generated by AI which can sometimes be misinterpreted. Please check any references attached.
Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the counter drugs and supplements such as vitamins and minerals.
Whenever I post about a trial or study, some people get excited without understanding that these new treatments and capabilities can very often take years to come to fruition and it’s also possible that clinical trials can be halted, or that national approval agencies will not approve the final product. Plus, not everyone will be eligible, so always check the exclusion and inclusion criteria in the relevant clinical trials document. Please bear that in mind when reading studies/clinical trials posted on RonnyAllan.NET
Thanks for reading.
Blog Facebook. Like this page please.
Personal Facebook. Like this page please.
Awareness Facebook Like this page please.
Follow me on X (formerly twitter)
Check out my online presentations
Check out my WEGO Health Awards
Long-axial field-of-view (LAFOV) systems have changed the field of molecular imaging. Since their introduction, many PET centres have installed these next-generation digital systems to provide
Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumours and Other Somatostatin Receptor 2-Expressing Tumours Read the
Here is the monthly summary of December 2025 on RonnyAllan.NET – Every share helps someone understand or even work towards a diagnosis, discovery of the
Summary of 2025 from Ronny It was a good year for my advocacy work but a difficult year personally which had some impact on my
15 Christmas celebrations since diagnosis. A thankful statement My Facebook memories today are full of Christmas activities including my first Christmas following diagnosis of advanced
A Global first for NET. Omni 128cm Total Body PET at the Peter MacCallum Cancer Centre in Melbourne Australia. According to Professor Michael Hofman, they
My diagnosis came with many strange words including, “carcinoid” and “neuroendocrine” ……… can you spell that please, I said to the doctor. I had a
Ronny Allan’s ‘PoNETry’ © series can be shared with poetry credit to: RonnyAllan.NET Thanks for reading Ronny I also have one about Lanreotide (or “butt
When I was diagnosed, I didn’t even feel ill. It was therefore a bit of a shock being told I had metastatic cancer, advanced enough to
Subscribe to get the latest posts sent to your email.
